Baxalta Inc Set To Abandon Talks With Ariad Pharmaceuticals, Inc.Rupert Hargreaves
According to a report published by Bloomberg this morning, Baxalta Inc. has abandoned its pursuit of Ariad Pharmaceuticals Inc. The report suggests that the deal broke down earlier this week, due to a disagreement over the price Baxalta was willing to pay for its smaller peer.
Shares of Ariad, which develops leukemia and lung cancer treatments, fell as much as 22% in . . .
This content is exclusively for paying members.
If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.